⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84973 | 0.71 | CTH (0.42) | — | |
| SCHEMBL20371752 | 0.67 | — | — | |
| SCHEMBL19604224 | 0.67 | — | — | |
| SCHEMBL14573902 | 0.59 | RARB (0.32) | — | |
| SCHEMBL1911601 | 0.57 | L3MBTL1 (0.32) | — | |
| SCHEMBL18681046 | 0.50 | L3MBTL1 (0.31) | — | |
| SCHEMBL19891802 | 0.50 | L3MBTL1 (0.31) | — | |
| SCHEMBL21719563 | 0.50 | L3MBTL1 (0.31) | — | |
| SCHEMBL21719353 | 0.50 | L3MBTL1 (0.31) | — | |
| SCHEMBL16886922 | 0.50 | L3MBTL1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240217979-A1 | GluN2 Subunit Selective Antagonists of the N-Methyl-D-Aspartate Receptors | UNIV EMORY (US) | 2024-07-04 | — | — | US | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| US-11661418-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661418-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | Université de Montréal (CA) | 2023-02-09 | — | — | US | disclosed |
| US-7482460-B2 | Doxepin analogs and methods of use thereof | HYPNION, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20080255073-A1 | COMPOUNDS FOR SUSTAINED RELEASE OF ORALLY DELIVERED DRUGS | XONOPORT, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080214539-A1 | Benzisoxazole Piperidine Compounds and Methods of Use Thereof | HYPNION, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080214539-A1 | Benzisoxazole Piperidine Compounds and Methods of Use Thereof | HYPNION, INC. | 2008-09-04 | — | — | US | disclosed |
| US-7408065-B2 | P2X7 receptor antagonists and their use | ASTRAZENECA AB (SE) | 2008-08-05 | — | — | US | disclosed |
| US-20080167296-A1 | 1,5,6,-Substituted-2-Oxo-3-Cyano-1,6a-Diaza-Tetrahydro-Fluoranthenes as Anti-Infective Agents | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-07-10 | — | — | US | disclosed |
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| US-20070043021-A1 | derivatives of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine for modulating sleep disorder; side effect reduction | HYPNION, INC. | 2007-02-22 | — | — | US | disclosed |
| US-20070015716-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070004752-A1 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. | 2007-01-04 | — | — | US | disclosed |